426
Participants
Start Date
January 25, 2018
Primary Completion Date
March 30, 2020
Study Completion Date
March 30, 2020
PPC-06 400 mg QD
Tepilamide Fumarate 400 mg tablet once per day
PPC-06 400 mg BID
Tepilamide Fumarate tablets 400 mg twice per day
PPC-06 600 mg
Tepilamide Fumarate tablets 600 mg twice per day
Placebo
white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
Site 103, New York
Site 177, New York
Site 104, New York
Site 146, Stony Brook
Site 161, Rochester
Site 166, Norfolk
Site 108, High Point
Site 116, Wilmington
Site 134, Mt. Pleasant
Site 132, Marietta
Site 124, Savannah
Site 152, Orange Park
Site 143, Hialeah
Site 145, Hialeah
Site 181, Hialeah
Site 149, Miami
Site 112, Miramar
Site 154, Pembroke Pines
Site 130, Coral Gables
Site 105, Miami
Site 174, Miami
Site 110, Sweetwater
Site 164, Miami
Site 123, Miami
Site 150, Tampa
Site 113, Tampa
Site 137, Clearwater
Site 172, New Port Richey
Site 165, Louisville
Site 131, Louisville
Site 142, Louisville
Site 118, Beachwood
Site 169, Cincinnati
Site 115, Indianapolis
Site 171, New Albany
Site 128, Clinton Township
Site 129, Fridley
Site 100, Rapid City
Site 179, Wheaton
Site 111, Kansas City
Site 139, Overland Park
Site 109, Omaha
Site 126, New Orleans
Site 119, Baton Rouge
Site 157, Bryant
Site 125, Rogers
Site 162, Houston
Site 102, Houston
Site 160, Bellaire
Site 159, Sugar Land
Site 106, San Antonio
Site 101, San Antonio
Site 148, Austin
Site 122, Nampa
Site 136, Orem
Site 167, Phoenix
Site 158, Phoenix
Site 170, Tempe
Site 144, Glendale
Site 127, Las Vegas
Site 180-, Las Vegas
Site 176, Los Angeles
Site 178, Los Angeles
Site 182, Los Angeles
Site 141, San Diego
Site 156, Murrieta
Site 133, Fountain Valley
Site 153, Fullerton
Site 121, Fresno
Site 107, Fremont
Site 155, Santa Rosa
Site 135, Burien
Site 147, Spokane
Site 114, Johnston
Lead Sponsor
Dr. Reddy's Laboratories Limited
INDUSTRY